Original Article

Serum WAVE3 is a diagnostic marker for patients with gastric cancer

Mei Xiao, Dongling Qu

Department of Health Management, Weifang People’s Hospital, Weifang 261599, China

Received March 21, 2016; Accepted May 27, 2016; Epub August 1, 2016; Published August 15, 2016

Abstract: Objectives: The present study was conducted to investigate the diagnostic significance of Wiskott-Aldrich syndrome verprolin-homologous 3 (WAVE3) in patients with gastric cancer (GC). Methods: The serum level of WAVE3 mRNA was examined by real-time quantity PCR (qRT-PCR). Chi-square test was applied to evaluate the relationship between WAVE3 expression and clinical characteristics. The diagnostic value of WAVE3 in GC was assessed via conducting the receiver operating characteristic (ROC) curve. Results: Serum level of WAVE3 mRNA was significantly higher in GC patients than that in healthy controls (P<0.001). Furthermore, high WAVE3 expression was associated with positive lymph node metastasis (P=0.036), deep tumor invasion (P=0.016) and high TNM stage (P=0.041). The ROC curve revealed that WAVE3 was a candidate biomarker for the diagnosis of GC, with the sensitivity of 81.5% and the specificity of 92.4%. The optimal cutoff point was 2.34, and the AUC was 0.861. Conclusion: WAVE3 is up-regulated in GC serum, which is significantly associated with aggressive clinical characteristics. WAVE3 may be a potential biomarker for GC diagnosis.

Keywords: WAVE3, diagnosis, ROC, gastric cancer

Introduction

Gastric cancer (GC) is one of the most frequently observed malignant digestive diseases, which is still a leading reason for cancer-related death in the world [1]. The morbidity of GC is high, especially in developing countries, including China [2, 3]. At the present time, patients with GC are frequently diagnosed at advanced stage, leading to poor outcomes [4, 5]. Thus, early detection is crucial for the prognosis of GC patients. The occurrence and development of GC are a multistep and multifactorial process, which is with the involvement of a variety of environmental and inherited factors [6-8]. Currently, the biomarkers based on genetic factors not only reveal the mechanisms of carcinogenesis in GC, but also exploit novel approaches for diagnosis, therapy and prognosis for the cancer patients. Therefore, in the present study we investigated the clinical significance of Wiskott-Aldrich syndrome verprolin-homologous 3 (WAVE3) in GC, which maybe a potential indicator for early detection.
WAVE3, a diagnostic marker for gastric cancer

invasion, which may be a therapeutic target [18]. However, the diagnostic value of WAVE3 in GC has been rarely reported.

The purpose of the study was to explore the diagnostic value of WAVE3 in GC. Serum WAVE3 levels in patients pathologically diagnosed with GC and healthy individuals were compared. In addition, we evaluated the association between WAVE3 level and clinical characteristics in GC patients, as well as its diagnostic significance. The present study may explore a novel diagnostic marker for GC, which may improve the management of GC.

Materials and methods

Patients and specimens

The present study was carried out in Second Affiliated Hospital. 119 patients pathologically diagnosed with GC were collected in the study, including 67 males and 52 females, with the average age of 52.35±12.65 years. None of them had received chemotherapy or radiotherapy before blood collection. Besides, 105 gender-age matched healthy individuals from the physical examination center of the hospital were recruited as healthy controls. 5 mL fasting blood samples were collected from all the participants and then centrifuged at 2500× rpm for 20 min to collect serum specimens. The serum specimens were stored at -80°C until use. The current study was permitted by the ethic committee of the hospital. All the participants or their family signed the informed consents before specimens’ collection.

RNA extraction and quantitative real-time quantity PCR (qRT-PCR)

Total RNA was isolated from all serum samples using the Trizol reagent (Invitrogen) according to the manufacturer’s instructions. Then RNA with high quality was adopted to synthesize the first strand of cDNA using the TaqMan microRNA assay protocol (Applied Biosystems, Foster City, CA, USA). QRT-PCR was applied to evaluate the relative expression of WAVE3 in serum specimens. QRT-PCR reaction was performed with a SYBR green I Master Mix kit (Invitrogen) in Applied Biosystems 7900 Fast Real-time PCR system. GAPDH was used as an internal control. Each sample was determined in triple and the expression of WAVE3 mRNA was measured by the 2−ΔΔCt method. The sequences of the primers used in the study were as followed: WAVE3 forward: 5’-TTCTAGCTCACTGCTTTCA-GG-3’, reverse: 5’-TGGCCTTCTCCATTTT3; GAPDH forward: 5’-TGCACCACCAACTGCTTA-GC-3’, reverse: 5’-GGCATGCACATGTGGTCATG-AG-3’. In addition, the protein level of WAVE3 was detected by immunohistochemistry.

Statistical analysis

All statistical analyses were carried out in SPSS 18.0 software. Graphs were plotted by GraphPad Prism 5. The continuous data were presented as mean ± SD. The expression differences of WAVE3 between GC serum and healthy controls were estimated via students’ t-test. The relationship between WAVE3 expression and clinical characteristics was estimated by Chi-square test. The receiver operating characteristic (ROC) curve was used to assess the diagnostic value of WAVE3 for GC. Statistical significance existed when P was less than 0.05.

Results

Expression of WAVE3 mRNA was increased in GC serum

QRT-PCR was applied to evaluate the relative mRNA level of WAVE3 in serum specimens collected from GC patients and healthy controls.
Results suggested that WAVE3 was significantly up-regulated in GC patients, compared with healthy control (P<0.001) (Figure 1). Immunohistochemistry analysis indicated that the protein level of WAVE3 was increased in GC patients, which was consistent with the mRNA level.

**Association between WAVE3 expression and clinical features of patients**

Chi-square test was performed to assess the relationship between WAVE3 expression and clinical features. Results listed in Table 1 indicated that high WAVE3 expression was significantly associated with positive lymph node metastasis (P=0.036), deep tumor invasion (P=0.016) and high TNM stage (P=0.041). No marked correlation was found between WAVE3 expression and age (P=0.670), gender (P=0.265) or differentiation (P=0.435).

**Diagnostic value of serum WAVE3 in GC**

The ROC curve was established to estimate the diagnostic value of serum WAVE3 in GC. Results shown in Figure 2 suggested that WAVE3 could discriminate GC patients from healthy individuals with the optimal cutoff point of 2.34. The AUC value was 2.34, with the sensitivity of 81.5% and the specificity of 92.4%.

**Discussion**

GC is a malignant tumor originating from the gastric mucosa epithelium, which is an aggressive cancer of the digestive tract. Most of the patients are at advanced stage when firstly diagnosed, because there are no typical characteristics at the early stage of tumor progression [19]. Recently, molecular biomarkers for early detection and progression of cancers have become a research hotspot. And numerous biomarkers have been reported to act as diagnostic or prognostic markers for GC patients. Su et al. showed that miR-18a was a candidate biomarker for GC and its overexpression predicted poor prognosis of GC patients [20]. In the study of Yang et al., overexpression of eEF1A2 was found to be associated with unfavorable outcomes in GC patients [21]. The study scheduled by Chen et al. demonstrated that long non-coding RNA H19 was significantly associated with GC initiation and development, which can serve as a biomarker for the cancer diagnosis and prognosis [22]. The genetic biomarkers combined with clinical characteristics may accurately confirm the patients with risk of GC, which can significantly improve the outcomes of the patients [23]. Therefore, more novel biomarkers for diagnose of GC are urgently needed.

As we all know, the progression of tumors are the consequences of a number of cellular events, such as deregulated proliferation, enforced migration, resistance to apoptosis and disordered microenvironment [24, 25]. WAVE3 has been proved to regulate the motility and invasion of cell lines, which is correlated with tumor occurrence [14, 18]. In the present study, we detected the diagnostic significance of WAVE3 in GC patients. Analysis results indicated that WAVE3 may be a potential indicator for GC diagnosis.

In the current study, we detected the serum level of WAVE3 in GC patients and healthy indi-
WAVE3, a diagnostic marker for gastric cancer

In addition, ROC curve was conducted to evaluate the diagnostic value of WAVE3 in GC. Results indicated that WAVE3 could distinguish the GC patients from the healthy individuals with high sensitivity and specificity. However, the mechanism of WAVE3 involving in GC initiation has not been identified in the present study. Gangarao et al. suggested that the interaction of WAVE3 and NFκB played important roles on the invasion and survival of cancer cells [28]. Heather et al. revealed that WAVE3 was involved in the plasticity and motility of lamellipodial dynamics [29]. These experimental results could provide research directions for our further studies in investigating the mechanism of WAVE3 in GC.

In a word, serum level of WAVE3 mRNA is significantly higher in GC patients than that in the healthy controls. Moreover, up-regulated WAVE3 is markedly associated with positive lymph node metastasis, deep tumor invasion and high TNM stage. WAVE3 may be a potential biomarker for the diagnosis of GC.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Dongling Qu, Department of Health Management, Weifang People’s Hospital, Weifang 261599, China. E-mail: opwiut-ghg@sina.com

References


WAVE3, a diagnostic marker for gastric cancer
